Free Trial
→ Federal Reserve Reveals Disturbing New Plan To Control Your Money (From Weiss Ratings) (Ad)tc pixel
OTCMKTS:HYPMY

Hypermarcas Q1 2025 Earnings Results & Report

Hypermarcas logo
$5.30 0.00 (0.00%)
As of 10/9/2026 09:45 AM Eastern

Hypermarcas reported Q1 2025 earnings on April 23, 2025. The company reported EPS of -$0.04, while revenue was $184.34 million.

Research:ProfileEarnings HistoryForecast

Earnings Announcement Details

Quarter
Q1 2025
Report Date
Time
After Market Closes

Hypermarcas EPS Results

Actual EPS
-$0.04
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Hypermarcas Revenue Results

Actual Revenue
$184.34 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Upcoming Earnings

Hypermarcas' next earnings date is estimated for Wednesday, November 11, 2026, based on past reporting schedules.

Conference Call Resources

Hypermarcas Q1 2025 Earnings FAQ

Hypermarcas (OTCMKTS:HYPMY) reported earnings of -$0.04 per share for Q1 2025. The report was announced on Wednesday, April 23, 2025.

Hypermarcas reported revenue of $184.34 million for Q1 2025.

Hypermarcas' next earnings date is estimated for Wednesday, November 11, 2026. MarketBeat tracks confirmed and estimated earnings dates for Hypermarcas on the company's earnings history page.

Hypermarcas Earnings Headlines

Hypermarcas (OTCMKTS:HYPMY) Sees Unusually-High Trading Volume - Should You Buy?
October 6, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31092953
Hypermarcas (OTCMKTS:HYPMY) Reaches New 12-Month High - Should You Buy?
October 5, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31087455
Federal Reserve Reveals Disturbing New Plan To Control Your Money
A Federal Reserve filing, Docket No. OP-1670, is drawing scrutiny for language that could expand the Fed's visibility into consumer bank transactions. A pilot program is reportedly already underway, with wider rollout at major banks possibly beginning this summer. Martin D. Weiss, PhD, founder of Weiss Ratings, breaks down what the document says and what steps account holders might consider.tc pixel
October 12 at 1:00 AM  |  Weiss Ratings (Ad)
Head to Head Comparison: NRx Pharmaceuticals (NASDAQ:NRXP) & Hypermarcas (OTCMKTS:HYPMY)
October 5, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31086043
Hypera ON ADR (HYPMY)
September 27, 2026  |  es.investing.comhttps://es.investing.com/equities/hypermarcas-sa-news
Hypera S.A. (HYPMY) Q2 2026 Earnings Call Transcript
August 11, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4934927-hypera-s-a-hypmy-q2-2026-earnings-call-transcript
See More Hypermarcas Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Hypermarcas? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Hypermarcas and other key companies, straight to your email.

About Hypermarcas

Hypermarcas (OTCMKTS:HYPMY) S.A. was a Brazilian consumer healthcare company that developed, manufactured and marketed pharmaceutical and healthcare products. Its portfolio included over-the-counter medicines, prescription products, vitamins and other consumer health brands sold through pharmacies and retail channels.

The company was historically associated with well-known Brazilian brands such as Benegrip, Biotônico Fontoura, Doril, Engov and Epocler. Hypermarcas also previously operated in personal care, beauty, household cleaning and other consumer categories, but divested many of those businesses as it concentrated on pharmaceuticals and healthcare.

In 2018, Hypermarcas changed its corporate name to Hypera S.A., adopting the Hypera Pharma identity. The company’s principal market has been Brazil, with its operations focused on serving the Brazilian healthcare and pharmaceutical market.

View Hypermarcas Profile
Earnings Tools